A Study Evaluating Autologous T Cells Patients with Relapsed or Refractory CD30 Positive Classical Hodgkin Lymphoma (CHARIOT) (H-46851)
A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients with Relapsed or Refractory CD30 Positive Classical Hodgkin Lymphoma (CHARIOT – TESSCAR001)
This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.
Age requirements: 12 Years to 75 Years (child, adult, older adult)
More information about this study can be found on clinicaltrials.gov.
NCT#/ClinicalTrials.gov ID: NCT04268706